Brief: Cormedix Announces Completion Of Enrollment In Phase Iii Respect Clinical Trial For Rezzayo
29/09/2025 13:58
Sept 29 (Reuters) - CorMedix Inc CRMD.O: CORMEDIX ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III RESPECT CLINICAL TRIAL FOR REZZAYO CORMEDIX INC - TOPLINE RESULTS FROM RESPECT STUDY EXPECTED IN Q2 2026 Source text: ID:nGNX3g0lTj Further company coverage: CRMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CorMedix
See all newsBrief: Cormedix Announces FDA Acceptance For Priority Review Of Supplemental NDA For Rezzayo
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
CorMedix Inc. reports results for the quarter ended June 30 - Earnings Summary